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Viral respiratory infections may be associated with the virus-induced asthma in adults as
well as children. Particularly, human rhinovirus is strongly suggested a major candidate for
the associations of the virus-induced asthma.Thus, in this review, we reviewed and focused
on the epidemiology, pathophysiology, and treatment of virus-induced asthma with special
reference on human rhinovirus. Furthermore, we added our preliminary data regarding the
clinical and virological ﬁndings in the present review.
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INTRODUCTION
More than 200 different types of viruses, such as human rhinovirus
(HRV), human metapneumovirus (HMPV), respiratory syncytial
virus (RSV), and human parainﬂuenza virus (HPIV), are known
to cause acute respiratory illness (ARI; Tsukagoshi et al., 2013).
We recently reported the issue of “virus-induced exacerbation in
asthma and chronic obstructive pulmonary disease” (Kurai et al.,
2013a), however, among these causative viruses, HRV is now rec-
ognized to have amajor impact on asthma pathogenesis (Fujitsuka
et al., 2011). From this perspective, we reviewed the literature
regarding the epidemiology of HRV-induced asthma in adults,
together with preliminary epidemiological data obtained at our
institution.
CLINICAL VIROLOGY OF HUMAN RHINOVIRUS
HRV belongs to the genus Enterovirus and family Picornaviri-
dae (Turner and Couch, 2007). HRV possesses a single strand
positive-sense RNA (ssRNA) genome of approximately 7.2 kb.
The viral capsid is composed of four viral proteins (VP1-4) which
are assembled into 60 protomers, resulting in a small icosahe-
dral structure with a diameter of about 28–30 nm (Turner and
Couch, 2007). Genetically, HRV is classiﬁed into three species;
HRV-A, -B, and -C (Simmonds et al., 2010). Furthermore, these
species of HRVhavemore than 150 genotypes (Andries et al., 1990;
Arakawa et al., 2012; Kiyota et al., 2013, 2014). Molecular epidemi-
ological studies suggest that the dominant species are HRV-A and
-C, while HRV-B is relatively rarely detected (Arakawa et al., 2012;
Kiyota et al., 2013). In particular, the VP1 and VP2 proteins have
variations in their amino acid sequences, accounting for the large
number of viral serotypes (Turner and Couch, 2007). The host
receptor for HRV in respiratory epithelial cells is the intracellu-
lar adhesion molecule 1 (ICAM-1, CD54) for the 84 major HRV
serotypes (HRV-A and -B), or low-density lipoprotein receptor
(LDLR) for the other minor HRV serotypes. The receptor for
HRV-C is not yet known. It has been suggested that the optimal
temperature for replication of HRV is relatively cool (33–35◦C),
which would limit infections to the upper airway; however, large
or medium sized airways lower in the respiratory tract are now
also considered cool enough for HRV replication, in spite of the
higher temperature of the lung parenchyma (37◦C; McFadden
et al., 1985). Therefore, HRV is potentially a causative agent of
more severeARI such as bronchiolitis and pneumonia (Turner and
Couch, 2007; Watanabe et al., 2010; Smuts et al., 2011; Arakawa
et al., 2012), and may be associated with virus-induced asthma
(Johnston et al., 1995; Linsuwanon et al., 2009; Fujitsuka et al.,
2011; Smuts et al., 2011). HRVmight therefore be involved in var-
ious ARIs and additional respiratory complications (Kiyota et al.,
2013). Lieberman et al. (2009) reported that the detection of any
virus include HRV, the sensitivity rates for nasopharyngeal swab
(73.3%) was superior than that of oropharyngeal swab (54.2%),
respectively.
VIRUS-INDUCED COLDS AND THEIR NATURAL COURSE
AMONG THE GENERAL POPULATION
The common cold is the third most common primary diagnosis
in ofﬁce visits (Hsiao et al., 2010), and this disease is generally self-
limiting, usually lasting up to 10 days (Fashner et al., 2012). Among
the general population, HRV infection causes common colds
at a frequency of 25–53% (Makela et al., 1998; van Gageldonk-
Lafeber et al., 2005). Tyrrell et al. (1993) reported that intranasal
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inoculation with either HRV serotypes 2, 9, and 14, coronavirus
type 229E, or RSV in healthy volunteers induced patterns of symp-
tomdevelopment whichwere not substantially different from each
other. However, individual signs or symptoms occurred earli-
est in HRV infections, then in coronavirus, and lastly in RSV,
appearing up to 5 days after inoculation, which demonstrated
the long incubation periods of RSV in volunteers (Tyrrell et al.,
1993).
HRV has been implicated in patients with acute otitis media,
exacerbation of chronic obstructive pulmonary disease, common
cold, and lower respiratory tract infections in neonates, the elderly
and immunocompromised. Arruda et al. (1997) researching the
frequency and natural history of HRV infections in adults during
autumn, demonstrated that the ﬁrst symptom noticed most often
was sore throat (40%) in HRV culture- or PCR-positive patients,
and stuffy nose in HRV-negative patients (27%), using nasal wash
specimens. Respiratory symptoms typically develop after 1–2 days
after inoculation in studies, and uncomplicated HRV infections
usually peak 2–4 days after inoculation. The median duration of
HRV colds is 1 week, but up to 25% lastmore than 2weeks (Gwalt-
ney et al., 1967; Rotbart andHayden, 2000). It should be noted that
in illness caused by HRV, viral shedding occurs naturally for up to
21 days, but predominantly over a 3–4 days period.
HRV INFECTION AMONG ASTHMATICS: IN VIVO OR IN VITRO
EXPERIMENTAL STUDIES
HRV-A type16 (HRV-16), a major group virus commonly used
for experimental human infection, and HRV-A type1 (HRV-1),
which has been used in animal models of HRV infection, are
closely related. Grunberg et al. (1999) reported that experimental
HRV-16 infection via nasal inhalation leads to a transient decrease
of FEV1.0 in patients with asthma, and this decreased lung func-
tion was correlated with enhanced cold symptoms and / or airway
hyperresponsiveness. Contoli et al. (2006) demonstrated that type
III interferon (IFN-λ) production levels in ex vivo cell cultures
derived from bronchial epithelial cells (BECs) and macrophages
obtained fromasthmatic patients, were lower than in those derived
from healthy controls. Furthermore, deﬁcient interferon-λ pro-
duction was correlated with HRV viral load, severity of clinical
symptoms and FEV1.0. Message et al. (2008) demonstrated that
the severity of intranasally inoculated HRV-induced clinical ill-
ness in asthmatic subjects was correlated to virus load and lower
airway virus-induced inﬂammation.
On the other hand, DeMore et al. (2009) reported that no dif-
ference in clinical symptoms, and patterns of viral shedding, was
noted between subjects with persistent allergic asthma and healthy
subjects after experimental infection with HRV. These different
results after experimental HRV infection in individual studies in
asthmatic patients and healthy subjectsmight be dependent on the
severity of the asthma of those subjects who enrolled in the studies.
Indeed, in several reports, neither defective IFN induction byHRV,
nor increased HRV replication was observed in primary human
BECs derived from subjects with well controlled asthma (Lopez-
Souza et al., 2009; Bochkov et al., 2010; Sykes et al., 2014). A few
animal models for rhinovirus infection have been showed because
a major group of HRV (i.e., HRV-16) did not bind mouse ICAM-
1. Only a minor group of HRV (i.e., HRV-1B) infected the mouse.
In this regard, Bartlett et al. (2008) generated a transgenic BALB/c
mouse expressing a mouse-human ICAM-1 chimeric receptor for
HRV-16 infection. This study also showed asthma exacerbation
model by intraperitoneally sensitized with ovalbumin with alu-
minum hydroxide followed by intranasal inoculation of HRV-1B
or UV-inactivated HRV-1B.
HRV AND ASTHMA EXACERBATIONS: CLINICAL FINDINGS
Althoughdata regarding virus respiratory infections (VRIs) as pre-
cipitators of asthma attacks in adults are less clear, Nicholson et al.
(1993) reported thatVRIs are as commonly linked to exacerbations
in adults as they are in children (Johnston et al., 1996; Fujitsuka
et al., 2011). This study showed that viruses were detected in 44%
of clinical exacerbative episodes with a decrease in peak expira-
tory ﬂow rate (PEFR) of 50 mL/minute or more, and the most
commonly identiﬁed virus was HRV, followed by coronaviruses
and parainﬂuenza viruses (Nicholson et al., 1993). Thus, the virus
most commonly detected in asthma exacerbations appears to be
HRV.
Although HRV is well known as the most frequent cause of
the common cold, the implications of HRV infection vary accord-
ing to respiratory diseases. Table 1 shows the frequency of HRV
infection in various adult respiratory diseases such as exacerba-
tion of asthma (Nicholson et al., 1993; Atmar et al., 1998; Tan
et al., 2003), common cold (Makela et al., 1998; van Gageldonk-
Lafeber et al., 2005), exacerbation of COPD (Seemungal et al.,
2001; Rohde et al., 2003; Tan et al., 2003; Beckham et al., 2005;
Papi et al., 2006; Hutchinson et al., 2007; Ko et al., 2007; McManus
et al., 2008; Kherad et al., 2010; Dimopoulos et al., 2012; Per-
otin et al., 2013), community acquired pneumonia (Jennings et al.,
2008; Johnstone et al., 2008; Johansson et al., 2010; Lieberman
et al., 2010; Fry et al., 2011; Wootton et al., 2011; Luchsinger et al.,
2013; Takahashi et al., 2013; Huijskens et al., 2014), exacerba-
tion of idiopathic pulmonary ﬁbrosis (Wootton et al., 2011), and
asymptomatic infection (Fry et al., 2011).
The risk of exacerbations of asthma in adults is elevated after
children return to school, and around December 25th (the Christ-
mas holiday in westernized countries), and this is likely to be due
to social interactions with children at these times. Prospective
monitoring studies using reverse transcription polymerase chain
reaction (RT-PCR) indicate that as many as 85% of acute asthma
exacerbations in children, and about 60% in adults, were associ-
ated with the presence of upper respiratory tract (URT) infections.
Corne et al. (2002) found that the detection rates of HRV in asth-
matic (10.1%) and healthy participants (8.5%) were similar, but
the LRT symptoms were signiﬁcantly more severe and longer last-
ing in the asthmatic group than in the healthy group based on one
deﬁnition of URT and LRT symptoms (Table 2; Johnston et al.,
1995).
There is no common antigen across all strains of HRVs;
therefore, no reliable diagnostic method for HRV infection has
been established using HRV antigens or HRV-speciﬁc antibody.
Although viral culture is the conventional method for HRV detec-
tion, culture methods are not practical in clinical settings for
the detection of HRV, because of its slow growing character
and requirement for speciﬁc culture conditions. Furthermore,
the diagnostic capability of molecular ampliﬁcation techniques
Frontiers in Microbiology | Virology May 2014 | Volume 5 | Article 226 | 2
Saraya et al. Asthma exacerbations and human rhinovirus
Table 1 | HRV infection and its frequency in acute and chronic respiratory diseases in adults.
Frequency (%) Reference
Exacerbation of asthma 26–36 Nicholson et al. (1993), Tan et al. (2003), Atmar et al. (1998)
Common cold 25–53 Makela et al. (1998), van Gageldonk-Lafeber et al. (2005)
Exacerbation of COPD 3–27 Tan et al. (2003), Perotin et al. (2013), Rohde et al. (2003), Seemungal et al. (2001), Papi et al. (2006),
Hutchinson et al. (2007), Ko et al. (2007), McManus et al. (2008), Kherad et al. (2010), Dimopoulos
et al. (2012), Beckham et al. (2005)
Community-acquired
pneumonia
2–12 Johnstone et al. (2008), Jennings et al. (2008), Lieberman et al. (2010), Johansson et al. (2010),
Takahashi et al. (2013), Luchsinger et al. (2013), Huijskens et al. (2014)
Exacerbation of idiopathic
pulmonary ﬁbrosis
5 Wootton et al. (2011)
Asymptomatic infection 2 Fry et al. (2011)
Table 2 | Respiratory symptoms.
Upper respiratory symtoms Lower respiratory symptoms
Runny nose Cough during the day
Sneezing Cough during the night
Blocked or stuffy nose Wheeze during the night
Itchy, sore, or watery eyes Difﬁculty breathing shortness of breath
Sore throat
Hoarse voice
Fever of shivery
Headaches or face aches
Aches or pains elsewhere
Cited and adapted from Johnston et al. (1995).
such as nucleic acid sequence-based ampliﬁcation and RT-PCR is
superior to those of culture methods (Loens et al., 2006).
PATHOGENESIS OF HRV-ASSOCIATED ASTHMA
EXACERBATIONS
Experimental HRV infections have been shown to lead to a long-
lasting excessive airway narrowing in volunteer subjects with
asthma (Cheung et al., 1995; Grunberg et al., 1999). Of note,
rhinovirus, unlike inﬂuenza and other viruses, causes minimal
cytotoxicity (Fraenkel et al., 1995), and the amount of epithelial
damage does not correlate with the severity of the symptoms.
HRV infection can cause additive or synergistic effects in exac-
erbation of asthma via the inﬂux of additional inﬂammatory
cells in the airways with preexisted inﬂammation, resulting in
airway cholinergic hyperresponsiveness (Nagarkar et al., 2010),
as an allergic response. The effects of HRV infection such as
enhanced contractility of airway smooth muscle (ASM) cell and
impaired relaxation to cholinergic or β-adrenaergic agonists are
attributed solely to binding of the virus to its host receptor
ICAM-1 on the ASM cell surface. This proasthmatic-like effect
was recognized even in the situation of complete inhibition of
viral replication in vitro, but not in the setting of pretreat-
ment of ASM with neutralizing antibody directed against for
ICAM-1 (Grunstein et al., 2001). Thus, the HRV attachment
to ICAM-1 itself can affects the contractility of ASM cells in
the absence of any cytopathic effects, and Chun et al. (2013)
reported that A 549 cells infected with HRV in vitro produced
a higher value of IL-8 and RANTES than those of RSV or ade-
novirus. In addition, only the combination of HRV with Der f1
(house dust mites antigen) acted synergistically to induce IL-8
production. These ﬁndings are the reason why the HRV can be a
major pathogen for acute exacerbation of asthma. We present a
schema for pathogenesis in HRV associated asthma exacerbations
(Figure 1), which requires the following steps, (1) HRV attach-
ment to airway epithelial cells, (2) an innate immune response
which leads to epithelial damage, (3) infection-related airway
remodeling.
ATTACHMENT TO AIRWAY EPITHELIAL CELLS
When RT-PCR is used to either supplement or replace conven-
tional culture techniques, viruses have been found in approx-
imately one half to three quarters of adults experiencing an
acute wheezing episode (Jackson and Johnston, 2010), and
the majority (59%) of viruses identiﬁed were HRVs (Nichol-
son et al., 1993). However, the evidence is weak, and mecha-
nisms are poorly understood. Initially, HRV-A and -B attach
to airway epithelial cells via ICAM-1 or LDLR (Kennedy et al.,
2012). The receptor or receptors for the recently identiﬁed
group HRV-C have yet to be clariﬁed. HRV-infected BECs
secrete a wide range of cytokines and chemokines such as
IL-1, IL-6, CCL5/RANTES (regulated on activation, normal
T cell expressed and secreted), CXCL8/IL-8, GM-CSF, and
CXCL10/interferon-inducible protein 10 (IP-10; Jackson and
Johnston, 2010; Proud, 2011), which induce neutrophilic, lym-
phocytic, and eosinophilic inﬂammation together with airway
hyperresponsiveness and airway remodeling (Wark et al., 2002;
Proud, 2011).
THE INNATE IMMUNE RESPONSE
Clearance of viral pathogens begins with interferon secretion, and
the underproduction of these factors has been postulated to lead to
viral-induced exacerbations. There are three types of interferons,
based on the receptors they bind: type I (IFN-α/β), type II (IFN-γ),
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FIGURE 1 | HRV attaches to airway epithelial cells via ICAM-1, LDLR, and
unknown receptors for HRV-C. HRV infected bronchial epithelial cells
secrete a wide range of cytokines (IFN-β, IFN-λ, IL-1, IL-6, GM-CSF) and
chemokines (CXCL10/IP-10, CCL5/RANTES, CXCL8/IL-8) together with NO,
VEGF, and EGF, FGF, amphiregulin and activin A. These cytokines and
chemokines attract various inﬂammatory cells such as DCs with upregulation
of FcεR1, lym, Eo, Neut, and Mφ. The VEGF, EGF, FGF, amphiregulin and activin
A promote the release of matrix proteins from ﬁbroblasts/myoﬁbroblasts,
which enhance the production of MMP9 from airway epithelial cells. These
phenomena could lead to airway remodeling (dotted area; i.e., thickening of
the lamina reticularis). HRV infection induces secretion of MUC5AC, which
impairs mucociliary clearance. DCs, dendritic cells; EGF, epidermal growth
factor; Eo, eosinophil; FGF, ﬁbroblast growth factor; GM-CSF, granulocyte
macrophage colony-stimulating factor; ICAM-1, intercellular adhesion
molecule 1; LDRL, low-density lipoprotein receptor; Lym, lymphocyte; MMP,
matrix metalloproteinase; Mφ, macrophage; Neut, neutrophil; NO, nitric oxide
synthase; RANTES, regulated on activation, normal T cell expressed and
secreted; VEGF, vascular endothelial growth factor.
and type III (IFN-λ). HRV infection induced epithelial expres-
sion of mRNA for both type I and type III IFNs, and it has been
suggested that impaired epithelial production of IFN-β and IFN-
λ in asthmatic subjects may contribute to viral exacerbations of
asthma (Wark et al., 2005; Contoli et al., 2006). Contoli et al. (2006)
showed signiﬁcant inverse correlations between ex vivo produc-
tion of IFN-λ and severity of symptoms, bronchoalveolar lavage
viral load and airway inﬂammation, and a strong positive corre-
lation with reductions in lung function during in vivo infection.
Genome-wide association studies showed that single nucleotide
polymorphisms involve in various diseases. Interferon-λpolymor-
phismsmay effect on the incidence of HRV infection (Russell et al.,
2014).
Message et al. (2008) reported virus load in asthmatic sub-
jects as being related to increased lower airway inﬂamma-
tion, and in turn increased lower airway inﬂammation being
related to increased symptoms, reductions in lung function,
and increases in bronchial hyperreactivity. These data suggest
a causal role for HRV infection in the pathogenesis of asthma
exacerbations.
Investigating virus-allergen interactions, Durrani et al. (2012)
demonstrated that another mechanism that increased expression
and cross-linking of the high-afﬁnity IgE receptor, FcεRI, on plas-
macytoid dendritic cells is associated with reduced HRV-induced
IFN-α and IFN-λ1 secretion, and allergic asthmatic children have
signiﬁcantly reducedHRV-induced IFN-α and IFN-λ1 production
after cross-linking of FcεRI.
Type 2, or inducible, nitric oxide synthase (iNOS) is the major
NOS isoform found in epithelial cells and can generate substantial
amounts of nitric oxide (NO). The NO molecules both inhibit
the replication of HRV in airway epithelial cells, and suppresses
HRV-induced cytokine production (Proud, 2005). Although the
measurement of fractional NO concentration in exhaled breath
(FENO) may be used to support the diagnosis of asthma (Dweik
et al., 2011), however, increasing of FENO seems to be not always
correlated with viral load during the period of HRV infection
(Sanders et al., 2004).
Other factors such as allergy, allergen exposure, tobacco
smoke, particulates, ozone, stress, and infections such as sinusitis
commonly contribute to exacerbations of asthma.
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HRV INFECTION AND AIRWAY REMODELING
Grainge et al. (2011) reported that repeated bronchoconstric-
tion in asthma promotes airway remodeling, and there is now
clear evidence that airway remodeling begins in early childhood,
and can be present even before clinical diagnosis of asthma is
established (Pohunek et al., 2005). Increasing evidence regard-
ing HRV-induced wheezing or exacerbation of asthma raises the
possibility that HRV infections could contribute to the initiation
and subsequent progression of airway remodeling, which involves
multiple factors such as increased epithelial release of Mucin5AC
(MU5AC), activin A, amphiregulin, matrix metalloproteinase
9 (MMP9), epidermal growth factor (EGF), ﬁbroblast
growth factor (FGF), and vascular endothelial growth factor
(VEGF).
HRV infection upregulates production of MUC5AC from
epithelial cells, which leads to airﬂowobstruction in asthma (Hew-
son et al., 2010). Activin A is a member of the TGF-β superfamily
and amphiregulin, a member of the EGF family, alters repair
processes (Leigh et al., 2008). Both activin A and amphiregulin
have been linked to subepithelial basement membrane thicken-
ing in asthma. MMP9 appears to have important roles in asthma
exacerbation and airway remodeling (Sampsonas et al., 2007).
Expression ofVEGF and its receptors is increased in asthmatic sub-
jects, and VEGF is the major proangiogenic activator in asthmatic
airways (Feltis et al., 2006; Simcock et al., 2007).
IMPACTS OF VIRAL INFECTION ON ASTHMA EXACERBATION:
PRELIMINARY DATA FROM THE KYORIN COHORT STUDY
Kuga et al. (2000) reported that 61.5% of adult asthmatic patients
with common cold suffered an asthma attack, and common cold
was signiﬁcantly associated with acute exacerbations of asthma.
They also stated that HRV infection might be important as the
virus was detected by RT-PCR in throat gargles (Kuga et al.,
2000). Virus-induced exacerbation of asthma is a critical issue
for the general physician. However, among asthmatic patients
with exacerbative status, distinguishing between those patients
which have VRIs, and those who do not, is difﬁcult. Further-
more, epidemiological data regarding adult asthma exacerbations
have been sparsely reported. To investigate the prevalence of
VRI in exacerbations of adult asthma in both hospitalized or
not-hospitalized patients, characterization of clinical and radi-
ological ﬁndings was performed. A prospective observational
cohort study was conducted at Kyorin University Hospital, Tokyo,
Japan from August 2012 to August 2013 (Kurai et al., 2013b).
All patients with respiratory symptoms associated with exac-
erbation of asthma were included, and samples were collected
by nasopharyngeal or oropharyngeal swab, and subjected to a
PCR method to detect common respiratory viruses. The 44
patients who were enrolled consisted of hospitalized (n = 15)
or not-hospitalized patients (n = 29; Table 3). In these two
groups, the subject’s backgrounds were similar for age, sex,
smoking rates, and duration of illness, however, the measured
value of SpO2 was signiﬁcantly lower in hospitalized patients
(87 ± 2.3%) than in non-hospitalized patients (96.2 ± 0.7%).
The incidence of VRI was signiﬁcantly higher in the former
group (46.7%, n = 7) than in the latter group (6.9%, n = 2;
p = 0.002). In the latter group, inﬂuenza virus alone was detected
in both patients. Furthermore, all hospitalized patients (100%,
n = 15) had wheezing or severe exacerbation based on the
ATS (American Thoracic Society)/ERS (European Respiratory
Society) statement (Reddel et al., 2009), whereas, among non-
hospitalized patients, only nine patients (31%) were considered
as having a severe exacerbation (p < 0.001), and 10 patients
(38.4%) had wheezing (p < 0.001). These ﬁndings suggested
that virus infection was certainly associated with the hypoxemia
and / or wheezing which resulted in a severe or serious asthma
attack, based on the Japanese guidelines (Ohta et al., 2011) or the
ATS/ERS statement (Reddel et al., 2009). Previous studies using
Table 3 | Comparison of the clinical characteristics of hospitalized and non-hospitalized asthma attack patients.
Hospitalized patients Non-hospitalized patients
Number of cases 15 29 Total 44
Number of virus positive cases 46.7% (n = 7) 6.9% (n = 2) p = 0.002**
Age 52 ± 5.8 60 ± 3.2 NS
Sex (M/F) 5/10 10/19 NS
Smoker 33.3% (n = 5) 24.1% (n = 7) NS
Duration of illness (years) 20.6 ± 4.7 18.0 ± 4.4 NS
SpO2(%) 87.0 ± .2.3 96.2 ± 0.7 p < 0.001***
Wheezing 100% (n = 15) 38.4% (n = 10) p < 0.001***
Severe or serious asthma attack on Japanese guideline† 80% (n = 12) 6.9% (n = 2) p < 0.001***
Severe attack on ATS/ERS statement†† 100% (n = 15) 31% (n = 9) p < 0.001***
WBC(/μl) 10,028 ± 1,568 9,850 ± 2,220 NS
CRP(mg/dL) 4.1 ± 1.5 1.1 ± 0.15 NS
lgE(IU/mL) 687 ± 191 545 ± 191 NS
†Deﬁned by Ohta et al. (2011), ††deﬁned by Reddel et al. (2009). ** p < 0.01, *** p < 0.001. All data are presented as (mean ± SD).
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PCR-based viral diagnostics found that viral respiratory infec-
tions were detected in up to 85% of exacerbations of asthma
in children and about 50% of exacerbations in adults (Nichol-
son et al., 1993; Johnston et al., 1995), which is similar to our
results. Serum inﬂammatory or allergic markers are not dif-
ferent between the hospitalized and non-hospitalized patients
(Table 3).
In hospitalized patients, the viruses identiﬁed were HRV
(n = 5), HMPV (n = 1), and RSV (n = 1). At the time of admis-
sion, the virus-positive group (n = 7) had signiﬁcant lower values
of SpO2 (81.4 ± 3.9%) than those of the virus-negative group
(n = 8, SpO2: 91.8 ± 1.3%, p < 0.007), and for the patients whose
data are available, the frequency of hypercapnea (PaCO2  45
Torr) was signiﬁcantly higher in the virus positive group (66.7%,
n = 4) than in the virus negative group (0%; p = 0.014; Table 4).
The mechanisms for hypercapnea in virus infected individuals
have not been elucidated. However, Cheung et al. (1995) reported
that HRV infection causes long lasting excessive airway narrowing
in response to methacholine in asthmatic subjects. We speculated
that smooth muscle might have a role in exaggerated airway nar-
rowing in virus positive asthmatic patients, as described by King
et al. (1999).
Interestingly, the incidence of ground glass opacities (GGO)
on high resolution computed tomography seemed to be higher
for virus-positive hospitalized patients than for virus-negative
patients, but it did not reach statistical signiﬁcance. For example,
Figure 2A shows a patchy GGO with thickening of interlobu-
lar septa in a 28-year-old woman who was admitted during an
asthma attack induced by HRV-A. Figure 2B also shows GGO in
a 62-year-old man with an asthma attack caused by HRV-C infec-
tion. These GGO in both patients could only be detected inHRCT,
not in chest X-ray.
These results suggested that HRV was the major cause of virus-
induced asthma, and was possibly involved in lower airway or
lung parenchyma features, appearing as GGO. Viral infection
signiﬁcantly exaggerated the respiratory status (low SpO2 and
hypercapnea) when compared to that of virus-negative asthma
exacerbative patients at the time of admission. Indeed, in recent
years, HRV has been recognized as a common cause of hospital
admission, both as an agent of bronchopneumonia and through
exacerbation of chronic pulmonary conditions, even in the elderly
over 65 years of age (Pierangeli et al., 2011).
Curiously, after initiation of treatment with intravenous
steroid, both the virus-positive and -negative groups had no signif-
icant difference in duration of respiratory failure, wheezing, days
in hospital, and even in the time required for steroid treatment.
TREATMENT
No established treatment for prevention of HRV-induced asthma
is available, and we describe the exploratory interventions as
follows.
INHALED CORTICOSTEROID
Inhaled corticosteroid (ICS) is the main drug for regular asthma
therapy. ICS treatment improved airway hyperresponsiveness in
asthmatic patients experimentally challenged with HRV, however,
ICS treatment did not reduce accumulation of inﬂammatory cells,
except for eosinophils in bronchial epithelium (Grunberg et al.,
2001). Double-stranded RNA (dsRNA), a viral product and a lig-
and for the Toll-like receptor-3 (TLR3), upregulates the expression
of inﬂammatory chemokines in airway epithelial cells. Matsukura
et al. (2013) reported that treatment of BEAS-2B cells with ﬂu-
ticasone propionate signiﬁcantly and dose-dependently inhibited
dsRNA-induced expressionof CCL5,CXCL8, andCXCL10protein
Table 4 | Clinical characterization of hospitalized patients with asthma attack based on the presence of virus infection.
Virus positive Virus negative
Number of hospitalized patients 7 8 Total 15
Age 49.4 ± 8.8 54.3 ± 8.2 NS
Sex (M/F) 3/4 3/6 NS
Smoker 28.6% (n = 2) 37.5% (n = 3) NS
Duration of illness (years) 28 ± 5.8 11.4 ± 5.1 NS
SpO2(%) 81.4 ± 3.9 91.8 ± 1.3 p = 0.007**
Wheezing 100% (n = 7) 100% (n = 8) NS
Severe or serious asthma attack on Japanese guideline† 100% (n = 7) 62.5% (n = 5) NS
Severe attack on ATS/ERS statement †† 100%(n = 7) 100%(n = 8) NS
PaCO2 ≥ 45Torr 66.7%(4/6) 0% (0/6) p = 0.014*
SpO2 ≤ 88% 71.4% (5/7) 22.2% (2/8) NS
Duration of respiratory failure (days) 5.7 ± 2.5 3.7 ± 1.8 NS
Duration of wheezing (days) 6.7 ± 1.1 7.1 ± 1.8 NS
Duration of steroid treatment (days) 13.7 ± 3.8 12.9 ± 3.5 NS
Duration of hospital stays (days) 7.3 ± 2.0 7.3 ± 1.8 NS
*p < 0.05, **p < 0.01. All data are presented as (mean ± SD).
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FIGURE 2 | (A) Shows a patchy GGO with thickening of interlobular septa in a 28-year-old woman who was admitted during an asthma attack induced by
HRV-A. (B) Also shows GGO in a 62-year-old man with an asthma attack caused by HRV-C infection.
and mRNA. To conﬁrm the effect on ssRNA, such as that of HRV,
would need further studies.
LEUKOTRIENE RECEPTOR ANTAGONIST
Leukotriene receptor antagonist was prescribed in asthmatic
patients with or without ICS. Montelukast treatment did
not improve asthma control or cold symptom scores when
HRV were experimentally inoculated into mild asthmatics,
or healthy subjects (Kloepfer et al., 2011). It is uncertain
whether leukotriene receptor antagonist treatment is effective
in the reduction of asthma symptoms associated with HRV
infection.
ANTI-IgE THERAPY
Zambrano et al. (2003) reported that high serum IgE levels in
mildly asthmatic children with experimental HRV infection may
be associated with enhanced lower respiratory symptoms and ele-
vation of inﬂammatory markers, such as nasal eosinophil cationic
protein and expired nitric oxide, than those of healthy subjects
and/or low IgE asthmatic patients. The prevalence of asthma was
closely associated with the serum IgE levels standardized for age
and sex (Burrows et al., 1989), and airway hyperresponsiveness
appears to be closely linked to the allergic diathesis, as reﬂected
by the serum total IgE level (Sears et al., 1991). Omalizumab,
an anti-IgE monoclonal antibody, was indicated in inadequately
controlled moderate-to-severe persistent allergic asthma patients
who were treated with high dose ICS. Durrani et al. (2012)
showed that the IgE receptor FcεRI is inversely associated with
IFN-α and IFN-λ1 secretion when plasmacytoid dendritic cells
derived from allergic asthmatic children were challenged with
HRV. Omalizumab downregulates FcεRI expression on dendritic
cells (Prussin et al., 2003), which may reduce exacerbation of
asthma associated with increased production of IFNs, through
FcεRI.
ANTI-VIRAL TREATMENT
No drugs are clinically used in HRV infection, although sev-
eral drugs have been tried for treatment and prevention of HRV
infection. These drugs are summarized in a review (Jacobs et al.,
2013). IFNs had a potential protective role in viral induced
asthma (Cakebread et al., 2011; Gaajetaan et al., 2013). Becker et al.
(2013) showed that exogenous IFN-α, IFN-β, IFN-λ1, and IFN-λ2
inhibited HRV replication in BECs from healthy donors.
MACROLIDE THERAPY
Macrolides are known to possess anti-inﬂammatory and
immunomodulatory actions extending beyond their antibacte-
rial activity in pulmonary inﬂammatory disorders (Takizawa et al.,
1995; Min and Jang, 2012). Erythromycin inhibits HRV infection
by reducing ICAM-1 expression on the surface of human tracheal
epithelial cells, and modulates inﬂammation by suppressing the
production of proinﬂammatory cytokines (Suzuki et al., 2002).
OTHER AGENTS
Yamaya et al. (2014) reported that the mucolytic drug ambroxol
hydrochloride, antibiotic drug of levoﬂoxacin (Yamaya et al.,
2012b), and bronchodilators (Tiotropium, Tulobuterol, and Pro-
caterol) for asthma or COPD (Yamaya et al., 2011, 2012a, 2013)
may have a beneﬁcial effect in HRV infection, by inhibiting HRV
replication and partly reducing ICAM-1 expression and acidic
endosome production, via the inhibition of NF-kappaB activation
(Yamaya, 2012).
SUMMARY
We reviewed the previous reports regarding HRV-induced asthma
exacerbations, together with our results from an institutional
prospective study. HRV is a major pathogen for asthma exac-
erbations, and certainly associated with more serious clinical
conditions such as hypoxemia or hypercapnea in hospitalized
patients. Further accumulation of evidence of virus-induced
asthma for multidisciplinary assessment would be helpful for
physicians in recognizing the condition or understanding the
pathogenic mechanisms.
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